editor
presid
american
clinic
laboratori
associ
acla
washington
dc
write
behalf
acla
member
applaud
natur
biotechnolog
clearli
delin
regul
vitro
diagnost
food
drug
administr
fda
rockvil
maryland
usa
would
set
back
promis
person
medicin
year
decad
wo
nt
repeat
point
made
march
emphas
neg
consequ
fda
regul
patient
real
clinic
laboratori
test
advanc
person
medicin
distinguish
individu
like
benefit
particular
drug
dosag
patient
diagnosi
probabl
develop
feder
oversight
center
medicar
medicaid
servic
clinic
laboratori
improv
amend
clia
test
quickli
modifi
take
advantag
import
new
import
develop
rapidli
advanc
field
medic
scienc
fda
beforemarket
review
laboratorydevelop
test
would
chill
effect
rapid
critic
import
innov
subject
anoth
layer
regul
drive
away
invest
need
valid
incorpor
test
modif
danger
introduc
delay
overlap
fda
regul
best
understood
context
genet
test
person
medicin
alreadi
achiev
mani
test
develop
laboratori
provid
healthcar
breakthrough
especi
infecti
diseas
cancer
aid
transform
deadli
diseas
manag
chronic
diseas
larg
part
laboratorydevelop
test
diagnos
manag
hiv
hiv
mutat
rapidli
antivir
drug
hiv
treatment
develop
laboratorydevelop
test
essenti
rapidli
incorpor
new
inform
identifi
drug
use
individu
therapi
allow
treatment
move
one
drug
suit
approach
much
individu
strategi
base
upon
uniqu
genet
natur
individu
diseas
test
develop
lab
also
critic
nation
public
health
defens
allow
identif
sever
acut
respiratori
syndrom
sar
coronaviru
avian
flu
west
nile
viru
although
mani
exampl
exist
underscor
laboratorydevelop
test
abil
respond
rapidli
new
often
menac
health
challeng
continu
allow
within
congression
establish
regulatori
framework
alreadi
exist
laboratori
test
subject
fda
regul
rare
lowvolum
test
genet
spinal
muscular
atrophi
gaucher
diseas
taysach
diseas
canavan
diseas
among
mani
remov
clia
lab
menu
longer
avail
parent
children
afflict
diseas
small
popul
would
avail
clinic
trial
test
wellestablish
medic
import
test
would
abl
meet
fda
requir
limit
disappear
furthermor
fda
preclear
preapprov
laboratorydevelop
test
could
commerci
offer
would
danger
imped
abil
nation
clinic
refer
laboratori
innov
quickli
would
profound
neg
impact
healthcar
deliveri
practic
medicin
would
close
import
public
health
safeti
valv
provid
laboratorydevelop
test
exampl
current
abil
flexibl
variou
laboratori
includ
academ
institut
respond
emerg
medic
need
enabl
offer
servic
would
never
gener
financi
oper
return
necessari
allow
broad
commerci
introduct
vitro
diagnost
test
kit
condit
mani
case
vitro
diagnost
devic
manufactur
ever
manufactur
kit
test
laboratori
requir
clear
test
fda
mani
test
simpli
would
made
avail
laboratori
offer
present
kit
manufactur
addit
test
broader
applic
also
would
find
difficult
make
way
market
health
human
servic
recent
person
medicin
note
ventur
capit
like
remain
primari
sourc
financ
young
innov
space
person
medicin
due
extraordinari
risk
associ
invest
healthcar
technolog
hh
report
goe
suggest
small
chang
regulatori
polici
reimburs
outlook
direct
impact
abil
emerg
firm
attract
necessari
invest
emerg
signific
new
barrier
entri
market
form
new
fda
premarket
requir
accompani
cost
almost
certainli
would
make
difficult
attract
need
invest
result
abil
new
compani
succeed
would
imped
significantli
allow
twentyfirst
centuri
healthcar
revolut
continu
acla
propos
regulatori
model
build
interag
coordin
center
medicar
medicaid
servic
fda
provid
publicli
transpar
test
registri
consist
principl
least
burdensom
regul
fill
identifi
regulatori
gap
avoid
overlap
potenti
conflict
requir
allow
participatori
approach
draw
expertis
industri
stakehold
sincer
hope
new
administr
lead
effort
acceler
person
medicin
commit
regulatori
balanc
allow
remark
scienc
progress
without
place
needless
burden
thought
regul
industri
